ID   SPHK1_HUMAN             Reviewed;         384 AA.
AC   Q9NYA1; Q8N632; Q96GK1; Q9HD92; Q9NY70; Q9NYL3;
DT   24-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=Sphingosine kinase 1;
DE            Short=SK 1;
DE            Short=SPK 1;
DE            EC=2.7.1.91 {ECO:0000269|PubMed:10802064, ECO:0000269|PubMed:20577214, ECO:0000269|PubMed:23602659};
GN   Name=SPHK1; Synonyms=SPHK, SPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10863092; DOI=10.1016/S0378-1119(00)00205-5;
RA   Melendez A.J., Carlos-Dias E., Gosink M., Allen J.M., Takacs L.;
RT   "Human sphingosine kinase: molecular cloning, functional
RT   characterization and tissue distribution.";
RL   Gene 251:19-26(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, SUBSTRATE
RP   SPECIFICITY, AND TISSUE SPECIFICITY.
RX   PubMed=10802064; DOI=10.1016/S0014-5793(00)01510-6;
RA   Nava V.E., Lacana' E., Poulton S., Liu H., Sugiura M., Kono K.,
RA   Milstien S., Kohama T., Spiegel S.;
RT   "Functional characterization of human sphingosine kinase-1.";
RL   FEBS Lett. 473:81-84(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBSTRATE SPECIFICITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.
RX   PubMed=10947957; DOI=10.1042/bj3500429;
RA   Pitson S.M., D'Andrea R.J., Vandeleur L., Moretti P.A.B., Xia P.,
RA   Gamble J.R., Vadas M.A., Wattenberg B.W.;
RT   "Human sphingosine kinase: purification, molecular cloning and
RT   characterization of the native and recombinant enzymes.";
RL   Biochem. J. 350:429-441(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Van Veldhoven P.P., Gijsbers S.;
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Mammary gland, Ovary, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Blood, Kidney, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH SPHKAP.
RX   PubMed=12080051; DOI=10.1074/jbc.M202841200;
RA   Lacana E., Maceyka M., Milstien S., Spiegel S.;
RT   "Cloning and characterization of a protein kinase A anchoring protein
RT   (AKAP)-related protein that interacts with and regulates sphingosine
RT   kinase 1 activity.";
RL   J. Biol. Chem. 277:32947-32953(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, AND NUCLEAR EXPORT SIGNALS.
RX   PubMed=14575709; DOI=10.1016/j.bbrc.2003.09.194;
RA   Inagaki Y., Li P.Y., Wada A., Mitsutake S., Igarashi Y.;
RT   "Identification of functional nuclear export sequences in human
RT   sphingosine kinase 1.";
RL   Biochem. Biophys. Res. Commun. 311:168-173(2003).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-193, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   INTERACTION WITH CIB1, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   197-PHE-LEU-198.
RX   PubMed=19854831; DOI=10.1074/jbc.M109.068395;
RA   Jarman K.E., Moretti P.A., Zebol J.R., Pitson S.M.;
RT   "Translocation of sphingosine kinase 1 to the plasma membrane is
RT   mediated by calcium- and integrin-binding protein 1.";
RL   J. Biol. Chem. 285:483-492(2010).
RN   [13]
RP   CATALYTIC ACTIVITY, FUNCTION, MUTAGENESIS OF GLY-82, AND
RP   PHOSPHORYLATION AT SER-225.
RX   PubMed=20577214; DOI=10.1038/nature09128;
RA   Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M.,
RA   Kim E.Y., Maceyka M., Jiang H., Luo C., Kordula T., Milstien S.,
RA   Spiegel S.;
RT   "Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin
RT   ligase TRAF2.";
RL   Nature 465:1084-1088(2010).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-364 IN COMPLEXES WITH
RP   SUBSTRATE ANALOGS AND ADP, CATALYTIC ACTIVITY, FUNCTION, ACTIVE SITE,
RP   AND MUTAGENESIS OF ASP-81.
RX   PubMed=23602659; DOI=10.1016/j.str.2013.02.025;
RA   Wang Z., Min X., Xiao S.H., Johnstone S., Romanow W., Meininger D.,
RA   Xu H., Liu J., Dai J., An S., Thibault S., Walker N.;
RT   "Molecular basis of sphingosine kinase 1 substrate recognition and
RT   catalysis.";
RL   Structure 21:798-809(2013).
CC   -!- FUNCTION: Catalyzes the phosphorylation of sphingosine to form
CC       sphingosine 1-phosphate (SPP), a lipid mediator with both intra-
CC       and extracellular functions. Also acts on D-erythro-sphingosine
CC       and to a lesser extent sphinganine, but not other lipids, such as
CC       D,L-threo-dihydrosphingosine, N,N-dimethylsphingosine,
CC       diacylglycerol, ceramide, or phosphatidylinositol.
CC       {ECO:0000269|PubMed:20577214, ECO:0000269|PubMed:23602659}.
CC   -!- CATALYTIC ACTIVITY: ATP + a sphingoid base = ADP + a sphingoid
CC       base 1-phosphate. {ECO:0000269|PubMed:10802064,
CC       ECO:0000269|PubMed:20577214, ECO:0000269|PubMed:23602659}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10947957};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=14 uM for sphingosine {ECO:0000269|PubMed:10947957};
CC         KM=20 uM for dihydrosphingosine {ECO:0000269|PubMed:10947957};
CC         KM=77 uM for ATP {ECO:0000269|PubMed:10947957};
CC       pH dependence:
CC         Optimum pH is 7.4. {ECO:0000269|PubMed:10947957};
CC   -!- SUBUNIT: Interacts with ACY1 (By similarity). Binds to calmodulin.
CC       Interacts with SPHKAP. Interacts with CIB1, the interaction occurs
CC       in a calcium-dependent manner. {ECO:0000250|UniProtKB:Q8CI15,
CC       ECO:0000269|PubMed:12080051, ECO:0000269|PubMed:19854831}.
CC   -!- INTERACTION:
CC       P07858:CTSB; NbExp=4; IntAct=EBI-985303, EBI-715062;
CC       P68104:EEF1A1; NbExp=2; IntAct=EBI-985303, EBI-352162;
CC       Q14192:FHL2; NbExp=7; IntAct=EBI-985303, EBI-701903;
CC       Q2M3C7:SPHKAP; NbExp=4; IntAct=EBI-985303, EBI-1803914;
CC       Q9Y4K3:TRAF6; NbExp=2; IntAct=EBI-985303, EBI-359276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.
CC       Note=Translocated from the cytoplasm to the plasma membrane in a
CC       CIB1-dependent manner.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NYA1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NYA1-2; Sequence=VSP_035453;
CC         Note=Variant in position: 34:A->T (in dbSNP:rs346803).;
CC       Name=3;
CC         IsoId=Q9NYA1-3; Sequence=VSP_047078;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in adult
CC       liver, kidney, heart and skeletal muscle.
CC       {ECO:0000269|PubMed:10802064}.
CC   -!- MISCELLANEOUS: Sphingosine 1-phosphate stimulates TRAF2 E3
CC       ubiquitin ligase activity, and promotes activation of NF-kappa-B
CC       in response to TNF signaling.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF266756; AAF73470.1; -; mRNA.
DR   EMBL; AF238083; AAF73423.1; -; mRNA.
DR   EMBL; AF200328; AAG01980.1; -; mRNA.
DR   EMBL; AK023393; BAB14558.1; -; mRNA.
DR   EMBL; AK292294; BAF84983.1; -; mRNA.
DR   EMBL; AK022402; BAB14028.1; -; mRNA.
DR   EMBL; AJ245504; CAB92131.1; -; mRNA.
DR   EMBL; AC090699; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89392.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89393.1; -; Genomic_DNA.
DR   EMBL; BC009419; AAH09419.1; -; mRNA.
DR   EMBL; BC014439; AAH14439.1; -; mRNA.
DR   EMBL; BC030553; AAH30553.1; -; mRNA.
DR   CCDS; CCDS11744.1; -. [Q9NYA1-2]
DR   CCDS; CCDS45785.1; -. [Q9NYA1-1]
DR   CCDS; CCDS59297.1; -. [Q9NYA1-3]
DR   RefSeq; NP_001136073.1; NM_001142601.1. [Q9NYA1-1]
DR   RefSeq; NP_001136074.1; NM_001142602.1. [Q9NYA1-1]
DR   RefSeq; NP_068807.2; NM_021972.3. [Q9NYA1-3]
DR   RefSeq; NP_892010.2; NM_182965.2. [Q9NYA1-2]
DR   RefSeq; XP_005257823.1; XM_005257766.2. [Q9NYA1-1]
DR   UniGene; Hs.68061; -.
DR   PDB; 3VZB; X-ray; 2.00 A; A/B/C=9-364.
DR   PDB; 3VZC; X-ray; 2.30 A; A/B/C/D/E/F=9-364.
DR   PDB; 3VZD; X-ray; 2.30 A; A/B/C/D/E/F=9-364.
DR   PDB; 4L02; X-ray; 2.75 A; A/B/C=9-364.
DR   PDB; 4V24; X-ray; 1.80 A; A/B=1-363.
DR   PDBsum; 3VZB; -.
DR   PDBsum; 3VZC; -.
DR   PDBsum; 3VZD; -.
DR   PDBsum; 4L02; -.
DR   PDBsum; 4V24; -.
DR   ProteinModelPortal; Q9NYA1; -.
DR   SMR; Q9NYA1; -.
DR   BioGrid; 114396; 11.
DR   IntAct; Q9NYA1; 56.
DR   MINT; MINT-226199; -.
DR   STRING; 9606.ENSP00000313681; -.
DR   BindingDB; Q9NYA1; -.
DR   ChEMBL; CHEMBL4394; -.
DR   DrugBank; DB08868; Fingolimod.
DR   GuidetoPHARMACOLOGY; 2204; -.
DR   SwissLipids; SLP:000000111; -.
DR   iPTMnet; Q9NYA1; -.
DR   PhosphoSitePlus; Q9NYA1; -.
DR   BioMuta; SPHK1; -.
DR   DMDM; 17369329; -.
DR   MaxQB; Q9NYA1; -.
DR   PaxDb; Q9NYA1; -.
DR   PeptideAtlas; Q9NYA1; -.
DR   PRIDE; Q9NYA1; -.
DR   DNASU; 8877; -.
DR   Ensembl; ENST00000323374; ENSP00000313681; ENSG00000176170. [Q9NYA1-2]
DR   Ensembl; ENST00000392496; ENSP00000376285; ENSG00000176170. [Q9NYA1-1]
DR   Ensembl; ENST00000545180; ENSP00000440970; ENSG00000176170. [Q9NYA1-1]
DR   Ensembl; ENST00000590959; ENSP00000468547; ENSG00000176170. [Q9NYA1-3]
DR   Ensembl; ENST00000592299; ENSP00000465726; ENSG00000176170. [Q9NYA1-1]
DR   GeneID; 8877; -.
DR   KEGG; hsa:8877; -.
DR   UCSC; uc002jrf.1; human. [Q9NYA1-1]
DR   CTD; 8877; -.
DR   DisGeNET; 8877; -.
DR   GeneCards; SPHK1; -.
DR   HGNC; HGNC:11240; SPHK1.
DR   HPA; HPA022829; -.
DR   HPA; HPA028761; -.
DR   MIM; 603730; gene.
DR   neXtProt; NX_Q9NYA1; -.
DR   OpenTargets; ENSG00000176170; -.
DR   PharmGKB; PA36070; -.
DR   eggNOG; KOG1116; Eukaryota.
DR   eggNOG; COG1597; LUCA.
DR   GeneTree; ENSGT00690000101761; -.
DR   HOGENOM; HOG000111460; -.
DR   HOVERGEN; HBG054796; -.
DR   InParanoid; Q9NYA1; -.
DR   KO; K04718; -.
DR   OMA; PWQREPR; -.
DR   OrthoDB; EOG091G06SM; -.
DR   PhylomeDB; Q9NYA1; -.
DR   TreeFam; TF354296; -.
DR   BRENDA; 2.7.1.91; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   SABIO-RK; Q9NYA1; -.
DR   SignaLink; Q9NYA1; -.
DR   SIGNOR; Q9NYA1; -.
DR   ChiTaRS; SPHK1; human.
DR   GeneWiki; Sphingosine_kinase_1; -.
DR   GenomeRNAi; 8877; -.
DR   PRO; PR:Q9NYA1; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000176170; -.
DR   CleanEx; HS_SPHK1; -.
DR   ExpressionAtlas; Q9NYA1; baseline and differential.
DR   Genevisible; Q9NYA1; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0017050; F:D-erythro-sphingosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0003951; F:NAD+ kinase activity; IEA:InterPro.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:BHF-UCL.
DR   GO; GO:0008481; F:sphinganine kinase activity; IDA:MGI.
DR   GO; GO:0038036; F:sphingosine-1-phosphate receptor activity; IMP:UniProtKB.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:MGI.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0042346; P:positive regulation of NF-kappaB import into nucleus; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IDA:UniProtKB.
DR   GO; GO:0006457; P:protein folding; TAS:Reactome.
DR   GO; GO:0032651; P:regulation of interleukin-1 beta production; IEA:Ensembl.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0046521; P:sphingoid catabolic process; NAS:UniProtKB.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006670; P:sphingosine metabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.50.10330; -; 1.
DR   InterPro; IPR017438; ATP-NAD_kinase_dom_1.
DR   InterPro; IPR001206; Diacylglycerol_kinase_cat_dom.
DR   InterPro; IPR016064; NAD/diacylglycerol_kinase.
DR   Pfam; PF00781; DAGK_cat; 1.
DR   SMART; SM00046; DAGKc; 1.
DR   SUPFAM; SSF111331; SSF111331; 2.
DR   PROSITE; PS50146; DAGK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calmodulin-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase.
FT   CHAIN         1    384       Sphingosine kinase 1.
FT                                /FTId=PRO_0000181357.
FT   DOMAIN       12    159       DAGKc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00783}.
FT   NP_BIND      22     24       ATP.
FT   NP_BIND      54     58       ATP.
FT   NP_BIND     111    113       ATP.
FT   NP_BIND     341    343       ATP.
FT   REGION       79     82       Substrate binding.
FT   MOTIF       147    155       Nuclear export signal 1.
FT   MOTIF       161    169       Nuclear export signal 2.
FT   ACT_SITE     81     81       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:23602659}.
FT   BINDING      86     86       ATP.
FT   BINDING     178    178       Substrate.
FT   BINDING     185    185       ATP.
FT   BINDING     191    191       ATP.
FT   MOD_RES     193    193       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     225    225       Phosphoserine.
FT                                {ECO:0000269|PubMed:20577214}.
FT   VAR_SEQ       1      1       M -> MSAQVLGFLRSWTPLPLAAPRGPAAAGNDAGAPAAT
FT                                APGGEGEPHSRPCDARLGSTDKELKAGAAATGSAPTAPGTP
FT                                WQREPRVEVM (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035453.
FT   VAR_SEQ       3      3       P -> PVVGCGRGLFGFVFS (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_047078.
FT   MUTAGEN      81     81       D->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:23602659}.
FT   MUTAGEN      81     81       D->N: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:23602659}.
FT   MUTAGEN      82     82       G->D: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:20577214}.
FT   MUTAGEN     197    197       F->A: Abolishes interaction with CIB1;
FT                                when associated with A-198.
FT   MUTAGEN     198    198       L->A: Abolishes interaction with CIB1;
FT                                when associated with A-197.
FT   CONFLICT      6      6       Missing (in Ref. 4; CAB92131).
FT                                {ECO:0000305}.
FT   CONFLICT     11     15       LPRPC -> ARL (in Ref. 4; CAB92131).
FT                                {ECO:0000305}.
FT   CONFLICT    114    115       NA -> KP (in Ref. 4; CAB92131).
FT                                {ECO:0000305}.
FT   CONFLICT    251    251       V -> M (in Ref. 2; AAF73423).
FT                                {ECO:0000305}.
FT   CONFLICT    260    260       V -> I (in Ref. 2; AAF73423).
FT                                {ECO:0000305}.
FT   CONFLICT    302    302       L -> F (in Ref. 2; AAF73423).
FT                                {ECO:0000305}.
FT   CONFLICT    325    325       V -> G (in Ref. 4; CAB92131).
FT                                {ECO:0000305}.
FT   CONFLICT    337    337       V -> M (in Ref. 3; AAG01980).
FT                                {ECO:0000305}.
FT   STRAND       13     21       {ECO:0000244|PDB:4V24}.
FT   TURN         26     29       {ECO:0000244|PDB:4V24}.
FT   HELIX        30     37       {ECO:0000244|PDB:4V24}.
FT   HELIX        39     44       {ECO:0000244|PDB:4V24}.
FT   STRAND       47     53       {ECO:0000244|PDB:4V24}.
FT   HELIX        59     66       {ECO:0000244|PDB:4V24}.
FT   HELIX        69     71       {ECO:0000244|PDB:3VZB}.
FT   STRAND       73     80       {ECO:0000244|PDB:4V24}.
FT   HELIX        81     92       {ECO:0000244|PDB:4V24}.
FT   HELIX        97    100       {ECO:0000244|PDB:4V24}.
FT   STRAND      105    109       {ECO:0000244|PDB:4V24}.
FT   HELIX       115    123       {ECO:0000244|PDB:4V24}.
FT   HELIX       131    144       {ECO:0000244|PDB:4V24}.
FT   STRAND      146    157       {ECO:0000244|PDB:4V24}.
FT   STRAND      162    172       {ECO:0000244|PDB:4V24}.
FT   HELIX       173    181       {ECO:0000244|PDB:4V24}.
FT   HELIX       182    190       {ECO:0000244|PDB:4V24}.
FT   HELIX       191    201       {ECO:0000244|PDB:4V24}.
FT   STRAND      206    214       {ECO:0000244|PDB:4V24}.
FT   HELIX       215    218       {ECO:0000244|PDB:4V24}.
FT   STRAND      230    232       {ECO:0000244|PDB:3VZB}.
FT   STRAND      249    251       {ECO:0000244|PDB:4V24}.
FT   STRAND      255    266       {ECO:0000244|PDB:4V24}.
FT   STRAND      285    291       {ECO:0000244|PDB:4V24}.
FT   HELIX       296    305       {ECO:0000244|PDB:4V24}.
FT   HELIX       306    308       {ECO:0000244|PDB:4V24}.
FT   HELIX       311    314       {ECO:0000244|PDB:4V24}.
FT   STRAND      319    331       {ECO:0000244|PDB:4V24}.
FT   STRAND      333    335       {ECO:0000244|PDB:4V24}.
FT   STRAND      337    340       {ECO:0000244|PDB:4V24}.
FT   STRAND      343    346       {ECO:0000244|PDB:4V24}.
FT   STRAND      350    362       {ECO:0000244|PDB:4V24}.
SQ   SEQUENCE   384 AA;  42518 MW;  EB04A7F2034C2DB0 CRC64;
     MDPAGGPRGV LPRPCRVLVL LNPRGGKGKA LQLFRSHVQP LLAEAEISFT LMLTERRNHA
     RELVRSEELG RWDALVVMSG DGLMHEVVNG LMERPDWETA IQKPLCSLPA GSGNALAASL
     NHYAGYEQVT NEDLLTNCTL LLCRRLLSPM NLLSLHTASG LRLFSVLSLA WGFIADVDLE
     SEKYRRLGEM RFTLGTFLRL AALRTYRGRL AYLPVGRVGS KTPASPVVVQ QGPVDAHLVP
     LEEPVPSHWT VVPDEDFVLV LALLHSHLGS EMFAAPMGRC AAGVMHLFYV RAGVSRAMLL
     RLFLAMEKGR HMEYECPYLV YVPVVAFRLE PKDGKGVFAV DGELMVSEAV QGQVHPNYFW
     MVSGCVEPPP SWKPQQMPPP EEPL
//
